Urothelial Carcinoma of the Bladder
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma of the Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Update: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer [Phase 3]
Phase 3 clinical trial investigating pembrolizumab (MK-3475) after surgery for localized muscle-invasive bladder cancer and locally advanced…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating whether circulating tumor DNA in blood can guide the use of immunotherapy after surgical removal of urot…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study [Phase 3]
A Phase 3 trial (MAIN-CAV) is evaluating the addition of cabozantinib to the immunotherapy drug avelumab for metastatic urothelial cancer, w…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [Phase 1]
Phase 1 trial evaluating [225Ac]Ac-AKY-1189 for solid tumors is currently recruiting, including urothelial carcinoma of the bladder and trip…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating modern immunotherapy for non-muscle invasive bladder cancer (urothelial carcinoma of the bladder) in BCG…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
A clinical trial update focusing on tumor budding and T1 sub-staging in urothelial bladder cancer; recruitment is not yet started.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer [Phase 3]
Phase 3 clinical trial update evaluating eribulin plus standard chemotherapy versus standard chemotherapy alone for metastatic urothelial ca…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer [Phase 2]
A Phase 2 study is testing pembrolizumab added to intravesical gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer, with the…
-
CLINICAL_TRIALS other · 2026-04-13Clinical Trial Update: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer [Phase 3]
A Phase 3 clinical trial is evaluating chemoradiotherapy with or without atezolizumab for localized muscle-invasive bladder cancer; the stud…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer [Phase 3]
Phase 3 trial status update for pembrolizumab after surgery in localized muscle-invasive bladder cancer and locally advanced urothelial carc…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the addition of tazemetostat to pembrolizumab in locally advanced or metastatic urothelial carcinom…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]
This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer
This entry notes a clinical trial (NCT07511517) evaluating the BladMetrix urine test to monitor recurrence in non-muscle invasive bladder ca…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC [Phase 2]
Phase 2 trial results of IO102-IO103 in combination with pembrolizumab as first-line therapy for metastatic non-small cell lung cancer, head…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study [Phase 3]
A Phase 3 trial (ARCHER) compares shorter-duration radiation therapy plus standard chemotherapy to standard radiation therapy with chemother…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant [Phase 1]
Phase 1 neoadjuvant trial targeting androgen signaling in AR-positive urothelial carcinoma of the bladder has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy [Phase 3]
Phase 3 trial update evaluating the optimal duration of immune checkpoint therapy for locally advanced and metastatic urothelial carcinoma; …
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy [Phase 3]
Relmada Therapeutics has withdrawn its Phase 3 trial of NDV-01 administered intravesically for BCG-unresponsive non-muscle invasive bladder …
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer [Phase 2]
A Phase 2 clinical trial evaluating preoperative immunotherapy combined with sacituzumab govitecan for muscle-invasive bladder cancer is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer [Phase 1]
Phase 1 clinical trial evaluating IO102-IO103 in combination with pembrolizumab for high-risk non-muscle invasive bladder cancer that is unr…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This clinical trial update describes the use of a live tumor diagnostic platform to evaluate immune checkpoint inhibitor responses across mu…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer [Phase 3]
Relmada Therapeutics is evaluating NDV-01, a sustained-release gemcitabine-docetaxel formulation, in Phase 3 for non-muscle invasive bladder…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors [Phase 2]
This Phase 2 trial update evaluates pemetrexed response in metastatic urothelial bladder cancer and other solid tumors based on tumor gene a…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma [Phase 2]
Phase 2 trial evaluating immune checkpoint inhibitors with or without propranolol hydrochloride in urothelial carcinoma; the study is curren…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder [Phase 2]
Phase II multicenter study comparing chemotherapy alone versus chemotherapy plus durvalumab (MEDI4736) in patients with lymph node–positive …